The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

The prospective multi-centre BIO-LivIQ trial will enrol 325 patients across 60 sites worldwide.

Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...

January 27, 2006-- Patients with conventional right ventricular pacemakers who develop severe heart failure may benefit from an upgrade to a biventricular pacing (BVP) system. The results of the small ...

A made-in-Calgary 4D heart model is transforming treatment for heart failure patients having a specialized pacemaker inserted, called cardiac resynchronization therapy (CRT). In a clinical trial, ...

Estimates suggest that around three million Americans are living with cardiac pacemakers, according to the American Heart Association. Now, thanks to MountainStar Healthcare, a new kind of pacemaker – ...

Background: The purpose of this article is to critically review the data accumulated to date from studies evaluating the hemodynamic and clinical effects of right ventricular apical pacing during ...